Conduit Pharmaceuticals Beta vs. Net Income
Conduit Pharmaceuticals' market capitalization and book value each provide useful but distinct information about the business. Intrinsic value for Conduit Pharmaceuticals synthesizes operating data into a single estimate that complements price and book value. Valuation methods compare these perspectives to frame context.
Note that Conduit Pharmaceuticals' intrinsic value and market price are different measures derived from different inputs. For Conduit Pharmaceuticals, key inputs include revenue of 2.72 B.
Conduit Pharmaceuticals Net Income vs. Beta Fundamental Analysis
Peer-based valuation metrics position Conduit Pharmaceuticals within its sector hierarchy. Conduit Pharmaceuticals stands at number one for beta across the peer group. It also stands at number one for net income across the peer group reflecting a 131,227,624 ratio of Net Income to Beta. Currently, Net Income is projected to increase noticeably based on multi-year reporting trends. A year ago, Conduit Pharmaceuticals reported Net Income at 237.52 Million. Comparative earnings metrics contextualize Conduit Pharmaceuticals.Conduit Net Income vs. Beta
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Conduit Pharmaceuticals |
| = | 1.81 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market and is calculated based on the Capital Asset Pricing Model (CAPM). However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Conduit Pharmaceuticals |
| = | 237.52 M |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Conduit Net Income Comparison
Conduit Pharmaceuticals is currently under evaluation for net income across the peer group.
Beta Analysis
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Conduit Pharmaceuticals will likely underperform.
Conduit Pharmaceuticals Profitability Projections
Without sustained profitability, Conduit Pharmaceuticals would eventually generate negative long-term returns for its investors. An accelerating profit trend for Conduit Pharmaceuticals is generally viewed as positive, while a declining one raises concerns.
| Last Reported | End Of Year Estimate | ||
| Accumulated Other Comprehensive Income | -97.2 M | -92.3 M | |
| Operating Income | 315.7 M | 331.5 M | |
| Net Loss | -16 M | -15.2 M | |
| Income Before Tax | 266.9 M | 280.2 M | |
| Total Other Income Expense Net | -48.8 M | -46.4 M | |
| Net Income | 237.5 M | 249.4 M | |
| Income Tax Expense | -29.3 M | -27.9 M | |
| Net Interest Income | -1.3 M | -1.3 M | |
| Interest Income | 14.9 K | 15.8 K | |
| Net Income Per Share | 6.00 | 6.30 | |
| Income Quality | 1.49 | 2.81 | |
| Net Income Per E B T | 0.80 | 0.84 |
Conduit Profitability Driver Comparison
Profitability drivers for Conduit Pharmaceuticals are the financial and operational factors with the greatest impact on its earnings. Investors must anticipate a wide variety of external disruptions that can affect Conduit Pharmaceuticals' profit margins, market performance, and overall investment attractiveness.
Earnings per Share Projection vs Actual
Use Conduit Pharmaceuticals in pair-trading
Pair trading with Conduit Pharmaceuticals can help investors hedge some company-specific exposure by balancing a long view with an offsetting position. Used properly, pair trading is less about prediction in isolation and more about identifying relative mispricing between related positions.
Conduit Pharmaceuticals Pair Trading
Conduit Pharmaceuticals Pair Trading Analysis
The information in the correlation table below can inform Conduit Pharmaceuticals tax-loss harvesting decisions, showing which instruments historically move in lockstep with Conduit Pharmaceuticals and can serve as viable temporary replacements.
Negative correlation assets provide natural hedges against Conduit Pharmaceuticals positions. When Conduit Pharmaceuticals's value declines, a negatively correlated instrument tends to rise, partially offsetting portfolio losses.
The combination of Correlation analysis and pair analysis offers hedging context for Conduit Pharmaceuticals. Cross-sector pair evaluation can broaden the hedging context for Conduit Pharmaceuticals. Pair trading frameworks rely on historical co-movement patterns that may not persist.Use Investing Themes to Complement your Conduit Pharmaceuticals position
Market capitalization should still be reviewed beside revenue, debt, and cash-flow quality. A theme workflow around Conduit Pharmaceuticals gives investors a structured way to compare related instruments before allocating. The resulting theme around Conduit Pharmaceuticals can be tuned for upside participation or tighter downside control depending on objectives.
Did You Try This Idea?
Run Obamacare Repeal Thematic Idea Now
Obamacare Repeal
Healthcare and drug manufacturing companies that will most likely be affected by the final stages of Obamacare repeal. The Obamacare Repeal theme has 56 constituents at this time.
Investors can hold the Obamacare Repeal Theme as a long-term basket or actively trade individual constituents to capture short-term price movement.
| View All Next | Launch |
Additional Tools for Conduit Stock Analysis
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |